Head-to-head evidence
Salmeterol (DISKUS) vs Ventolin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Salmeterol (DISKUS)
Marketed by GlaxoSmithKline
NCT00395304 · Phase 3 · completed
This was a rigorously designed, fully blinded, randomized crossover trial with a clinically meaningful composite primary measure, but the results available here do not show how the fluticasone-plus-salmeterol arm specifically compared with the other step-up therapies, so the salmeterol-specific effect cannot be confirmed from this data.
Next expected readout: June 2027 · NCT06676319 (registry estimate)
Ventolin
Developed by GlaxoSmithKline
NCT01076322 · Phase 3 · completed
The study randomized participants to treatment sequences and included Ventolin as the active comparator, but it was open-label and small, with an estimated 17 participants. Its primary endpoint, change in FEV1, is a clinical lung-function measure, but no results are posted to show whether the comparison was favorable for Ventolin or met its prespecified objective.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Salmeterol (DISKUS)'s landscape · Ventolin's landscape